Efficacy of taxane plus ramucirumab as second-line therapy in patients with HER2-negative advanced gastric cancer who experienced early progression on first-line chemotherapy (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1070P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Gastric Cancer • Oncology • Solid Tumor • HER-2
|
|
Rikako Yamamoto; Yuichiro Nishibori; YUKI NAKATANI; Yuko Akaishi; Ayako Tanaka; Kohei Akiyoshi; Shinya Tokunaga; Haruko Daga
|